Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Teva and Active Biotech complete enrollment in phase III ALLEGRO clinical trial of laquinimod

Nov. 19, 2008

Antidepressant and antipsychotic activity reported with Wyeth's WS-50030

Nov. 19, 2008

Preclinical profile of sanofi-aventis' novel histamine H3 antagonist reported

Nov. 19, 2008

Novel activin receptor type IIB proven effective in murine model of ALS

Nov. 19, 2008

Preclinical activity of PF-03800130 shows benefit in bipolar disorder-associated mood symptoms

Nov. 18, 2008

Novel dopamine D3 receptor agonists and antagonists described by Pfizer

Nov. 18, 2008

Thalidomide not effective in treating amyotrophic lateral sclerosis

Nov. 18, 2008

New therapeutic agents for neurological disorders reported in recent patent literature

Nov. 18, 2008

Studies show analgesic efficacy of ARRY-797 in postsurgical dental pain

Nov. 18, 2008

New glycine transporter GlyT1 inhibitor profiled at Merck & Co.

Nov. 17, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...